LIFECORE BIOMEDICAL INC
LFCRNASDAQTrading Snapshot
- Day Range
- $156.95 – $159.45
- 52-Week Range
- $3.63 – $8.98
- Volume
- $2.61B
- Avg Volume
- $3.22B
- Shares Outstanding
- 37.5M
- Next Earnings
- Oct 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $129M
- Last Q Revenue
- $34M
- P/E Ratio
- -5.9
- P/S Ratio
- 2.0x
- EPS (TTM)
- $-0.99
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +8.9%
Why Investors Own LFCR
- ✓High-growth profile — revenue up +48.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 53% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
LIFECORE BIOMEDICAL INC
LFCR
StockOtter · stockotter.spaceAbout LIFECORE BIOMEDICAL INC
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
LIFECORE BIOMEDICAL INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift LFCR price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
LIFECORE BIOMEDICAL INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.